Search academic texts

Information × Registration Number 0215U007135, 0114U001063 , R & D reports Title To optimize the treatment of patients with "triple negative "metastatic breast cancer popup.stage_title Head Syvak Lyubov Andriyivna, Registration Date 13-02-2015 Organization National Cancer Institute popup.description2 Object of study - 42 metastatic triple negative breast cancer patients, who were administered chemotherapy with САР and ТС regimens. Aim of the study -to increase the efficacy of the treatment of metastatic triple negative breast cancer patients by using of the most effective chemotherapy regimens based on clinical and laboratory prognostic factors and individual sensitivity to chemotherapy drugs. Methods of study and equipment: clinical, laboratory, instrumental, statistical; US apparatus "Aloca", hematologic analyzer ВС-3000, chemistry analyzer "Vitros", spectrophotometer "Thermo", high speed centrifuge "Biofuge", thermostate "Termit". As a result of combined clinical (complaints, physical data), laboratory (common blood count, blood chemistries, urinalysis), instrumental (ECG, echocardiography, chest x-ray, abdominal ultrasound or CT of the chest, abdomen and pelvis with contrast enhancement) research and analysis of molecular genetic parameters (gene polymorphism GSTP1, MTHFR, protein expression ITSN2) during chemotherapy for standard regimens CAP and TC (4-6 cycles) in patients with metastatic triple negative breast cancer found that regimens have moderate (II-III grade) toxicity, the main manifestations of which were gastrointestinal (91.2% and 87.6%) and hematological (68 4% and 71.2%). The most important prognostic factors of toxicity of chemotherapy in patients with metastatic triple negative breast cancer are the age older 45 years, concomitant diseases, particularly cardiovascular and gastrointestinal, cancer stage, previous treatment and the presence of the mutant allele G of the gene GSTP1 and T allele of the gene MTHFR. The level of ITSN2 gene expression in breast cancer samples may be an independent prognostic factor for predicting the absence of relapses. Elevated levels of the long isoform of the gene ITSN2 in patients with ER (-) PR (-) HER2 / neu (-) and poor prognosis may be an additional prognostic factor that needs further study. Product Description popup.authors А.Аскольський М. Кліманов Н. Касап Н. Майданевич С. Лялькін popup.nrat_date 2020-04-02 Close